The quiet corridors of Oushadhi, Kerala's premier public sector pharmaceutical company, just got louder with the footsteps of investigators. The Vigilance and Anti-Corruption Bureau (VACB) has officially begun a preliminary enquiry into allegations of financial irregularities that have shaken the AYUSH department's flagship enterprise.

Key facts

  • Vigilance probe initiated September 3, 2026
  • Health Minister requested investigation following audit reports
  • Finance Inspection Wing conducting parallel inquiry
  • FIR to be filed if preliminary findings warrant

Minister's Directive Sparks Probe

Health Minister K. Muraleedharan didn't wait for whispers to become shouts. After receiving damning audit reports and multiple complaints about Oushadhi's financial and operational practices, he took decisive action. His letter to the Home Minister specifically requested a VACB preliminary enquiry—a move that shows how seriously the government is taking these allegations.

Double-Barreled Investigation

While Vigilance begins its work, Muraleedharan has also directed the Principal Secretary (Health) to initiate a separate, detailed inquiry through the Finance Inspection Wing. This two-pronged approach suggests the government wants to leave no ledger unturned. The VACB will file an FIR and launch a full investigation if their initial findings confirm the need for deeper scrutiny.

What Comes Next

All eyes now turn to the investigators. The preliminary enquiry will determine whether there's enough evidence to warrant criminal proceedings. For Oushadhi, a company trusted with producing traditional medicines for Kerala's healthcare system, the stakes couldn't be higher. The coming weeks will reveal whether these allegations hold weight—and how deep any potential irregularities might run.